Stocks · News reference

Wedbush Maintains Outperform on Stoke Therapeutics, Raises Price Target to $40

Aug 4, 2026, 12:48 PMBenzinga Newsdesk

Wedbush analyst Laura Chico maintains Stoke Therapeutics (NASDAQ:STOK) with a Outperform and raises the price target from $38 to $40.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaOct 12, 2026, 12:07 PMBenzinga Newsdesk
Stoke Therapeutics Presents Data For STK-002 Supporting Disease-Modifying Potential In Autosomal Dominant Optic Atrophy At AAO 2026 Annual Meeting
–ADOA is the most common inherited optic nerve disorder and is primarily caused by variants in the OPA1 gene that result in insufficient levels of OPA1 protein, leading to progressive and irreversible vision
STOK
BenzingaOct 5, 2026, 11:10 AMBenzinga Newsdesk
Stoke Therapeutics Says FDA Willing To Accept Planned Phase 3 Cognition And Behavior Analysis For Zorevunersen In Dravet Syndrome
BIIB STOK
SEC EDGARSep 25, 2026, 8:05 PMSEC EDGAR
8-K filing — Stoke Therapeutics, Inc. (STOK)
Filed: 2026-09-25 AccNo: 0001193125-26-402820 Size: 137 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
STOK
BenzingaSep 4, 2026, 8:00 AMBenzinga Newsdesk
Stoke, Biogen Report Lasting Seizure Reductions In Dravet Syndrome Study
Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (NASDAQ:BIIB) today announced presentations
BIIB STOK